ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndromeA high proportion of patients had…
Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England &…
New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with…
Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a…
SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies designed to…
DOYLESTOWN, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused…
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the…
New data show continued durability of response over 14 months with humoral immune responses increasing over time LAWRENCEVILLE, N.J., May…
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;…
Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of 50.0% and mPFS of 7.4…